Advice
in the absence of a submission from the holder of the marketing authorisation:
epoetin alfa (Eprex®) is not recommended for use within NHSScotland.
Indication under review: treatment of symptomatic anaemia (haemoglobin concentration of ≤10g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (<200 mU/mL).
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice359KB (PDF)
Medicine details
- Medicine name:
- epoetin alfa (Eprex)
- SMC ID:
- SMC2164
- Indication:
- Treatment of symptomatic anaemia (haemoglobin concentration of ≤10g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (<200 mU/mL).
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 March 2019